Southern Research scientists develop an assay to find a cure for Zika
March 22, 2016 | Southern Research
BIRMINGHAM, Ala. – As reports of the Zika virus outbreak began to emerge from Brazil and portions of South and Central America, infectious disease researchers in the Drug Discovery labs of Southern Research were already taking steps to help combat its spread.
Today, Southern Research is proud to announce the development of a unique antiviral assay – a test that can be used by researchers worldwide to detect the virus in infected cell cultures. The assay is immediately available to meet the requirements of international clients. In addition, teams of experienced scientists at Southern Research are working to develop in vivo models that can be used to evaluate vaccines and therapeutic approaches aimed at preventing the further spread of Zika virus disease.
“Southern Research is uniquely positioned to support the efforts of the global scientific community as we work collectively to better understand, and ultimately stop the spread of this disease,” said Dr. Jonathan Rayner, Director of Infectious Disease Research at Southern Research in Birmingham. “With such a wide variety of skills and backgrounds under our roof, this team is comprised of experts from a number of different fields, including drug discovery, mosquito-borne infectious disease research, and biomedical engineering. This assay represents a crucial step in the global search for a vaccine, and we’re proud to be able to contribute to the growing body of science in this impactful way.”
Zika is a mosquito-borne virus that is thought to cause birth defects such as microcephaly in newborn children, if transmitted to women during the early stages of pregnancy. Earlier this year, the World Health Organization declared the spread of Zika a Public Health Emergency of international concern, and has since coordinated a global response. Southern Research has been able to support these efforts by leveraging their assay development and drug discovery experience.
Southern Research’s infectious disease research team focuses on a wide array of human infectious diseases including programs involved in the HIV Cure Initiative, Biodisease, Influenza clinical trial support, Dengue virus vaccine evaluations, Hepatitis and Poliovirus.
Drug development is deeply ingrained in the fabric of Southern Research. To date, research teams from the institute have discovered and developed seven cancer medications. Several of these drugs are currently being used by pediatric oncologists as an effective treatment in the fight against childhood cancer.
About Southern Research
Southern Research is a not-for-profit 501(c)(3) organization with more than 400 scientists and engineers working across four divisions: drug discovery, drug development, engineering, and energy and environment. We work on behalf of the National Cancer Institute, National Institutes of Health, the U.S. Department of Defense, the U.S. Department of Energy, NASA, major aerospace firms, utility companies, and other private and government organizations to solve the world’s hardest problems. Founded in 1941, Southern Research is headquartered in Birmingham with additional laboratories and offices in Wilsonville and Huntsville, Frederick, Maryland, Durham, North Carolina, Cartersville, Georgia, and Houston. Visit southernresearch.org for more information.
Drug Development, Drug Discovery, In The News, Infectious Disease Research, Industry Insights
Vaccine Candidate TNX-1800 Protected Both Upper and Lower Airways After Challenge with SARS-CoV-2, Suggesting an Ability to Block Forward Transmission
TNX-1800 is Based on a Proprietary Vaccine Platform Designed to Stimulate Long Term T cell Immunity
CHATHAM, NJ, March 25, 2021 – ...
In honor of Women’s History Month and Histotechnology Professionals Day, Southern Research wants to take a moment to recognize our team of histotechnologists and their team leader, LaVinia Ray. She was deemed by the National Society of Histotechnology to be the 2020 Histotechnologist of the Year...
On the 16th of November, 2020, Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, announced preliminary results for a live attenuated COVID-19 vaccine candidate engineered to express the SARS-CoV-2 (CoV-2) spike protein after vaccination. The research is part of an o...